triple-combo data slam dunk recapitul tripl
wait proteostasi tripl data first quarter
wednesday march market open vertex releas interim data
second set highli anticip phase tripl combin studi
symdeko iva/tez met primari endpoint four week combo
produc maximum mean absolut improv percent predict forc
expiratori volum one second percentag point het/min
heterozyg minim function mutat cystic fibrosi cf
patient compar tripl placebo maximum mean absolut improv
percentag point ad symdeko
homozyg popul compar symdeko alon phase data
strong recapitul phase ii data set similar vertex tripl
two vertex tripl combo set bar high upcom competit
view key catalyst vertex share proteostasi pti triple-
combo symdeko result consist vertex symdeko
triple-combo result achiev
improv het/min homozyg patient respect similar
tripl combin vertex plan wait full data choos
best regimen submit regulatori approv global avail second
quarter compani plan submit nda fda third quarter
follow europ fourth quarter
combo data expect first quarter earlier studi potenti
corrector double-combo led maximum mean absolut improv
percentag point mmol/l decreas sweat chlorid
homozyg patient seemingli compar better symdeko triple-combo data
amplifi expect first quarter
compet tripl combo achiev least improv
homozyg het/min patient accompani mmol/l drop sweat
chlorid believ view competit vertex expect vertex share
come current level competit fail meet mark see sizabl
upsid vertex share monopol cf market near futur
return equiti ttm
biopharmaceut compani focus develop commerci therapi
cystic fibrosi compani lead asset kalydeco kalydeco lumacaftor combo registr next-
gener combin clinic develop
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
maintain market perform rate increas fair-valu estim vertex share
base increas probabl success vertex tripl combo reach market
await competit triple-combo data proteostasi expect first quarter might highli
impact vertex share npv model valu compani cf franchis per share togeth net cash
per share end deriv fair valu vertex share model includ valu
program cf gene therapi program outsid cf excit scientif medic breakthrough
led vertex pois solv cf problem market perform thesi vertex share sole base
view competit market dynam vertex execut phase studi tripl combo proof-of-concept data
proteostasiss tripl combo also read first quarter competitor data par vertex tripl
combo vertex share might neg affect data match vertex triple-combo profil expect
vertex share significantli appreci
composit two vertex tripl combo evalu phase program symdeko tezacaftor
ivacaftor symdeko tripl combo studi het/min mutat one
allel minim function mutat popul homozyg popul studi
design support ex-u registr compani strategi test two differ next-gen corrector-bas
combin parallel intend help identifi benefici regimen patient maxim speed
market notabl het/min studi primari efficaci assess week safeti assess week
much-acceler develop timelin compar kalydeco orkambi whose durat pivot
studi six month efficaci one year safeti follow-up expect full data avail second
quarter facilit submiss nda fda third quarter europ fourth quarter
data use compani seek approv patient het/min homozyg
patient concurr
upcom catalyst includ triple-combo data proteostasi first quarter data
tripl combo second quarter nda submiss tripl regimen third quarter ema
submiss tripl regimen fourth quarter initi proof-of-concept data vertex program outsid cf
next one two year
risk market perform rate vertex includ stronger competit data cf setback relat
clinic preclin business-develop activ
dollar thousand drugpeak salesstag ofdevelopmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuekalydeco cystic fibrosi gate marketedfebruari combo cystic homozyg marketedjuli orkambi feb combofor cystic phase year-end present valu addit gain loss fair includ cost directli relat program abovesourc compani report william blair compani estimatesexhibit pharmaceut incorporatedsum-of-part fair valu import disclosur
